Camrelizumab plus apatinib in patients with advanced or refractory chordoma: A single-arm, open-label, phase 2 trial.

阿帕蒂尼 医学 耐火材料(行星科学) 打开标签 外科 肿瘤科 随机对照试验 总体生存率 物理 天体生物学
作者
Cheng Zhi Yang,Qi Jia,Chenglong Zhao,Haifeng Wei,Tielong Liu,Xinghai Yang,Jian Jiao,Zhipeng Wu,Jian Zhao,Weiwei Zhou,Xiaomei Ma,Yan Lou,Eric W. Zhang,Jingyu Xing,Hao Zhang,Jianru Xiao
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl): 11503-11503 被引量:1
标识
DOI:10.1200/jco.2025.43.16_suppl.11503
摘要

11503 Background: The limited efficacy of current treatments for chordoma underscores the need for novel therapeutic options. Immune checkpoint inhibitors (ICI) have changed the landscape of cancer treatment but are rarely investigated for chordomas. Additionally, no established biomarkers reliably predict the efficacy of ICI and targeted therapies in this context. Methods: This investigator-initiated, single-arm, phase 2 trial evaluated the efficacy and safety of camrelizumab (anti-programmed death 1, PD-1) combined with apatinib (a tyrosine kinase inhibitor) in patients with advanced or refractory chordoma. Eligible patients received camrelizumab (200 mg intravenously every 2 weeks) and apatinib (250/500 mg orally daily) in 28-day cycles. The primary endpoint was objective response rate (ORR) assessed per RECIST 1.1 and Choi criteria. Secondary endpoints were median progression-free survival (PFS), overall survival, disease control rate (DCR) and safety. Next-generation sequencing (NGS) and fluorescence in situ hybridization (FISH) were used to explore predictive biomarkers. The trial is registered on Chictr.org.cn (ChiCTR2100042938). Results: Between September 2021, and October 2024, 38 patients were screened, and 33 were enrolled for efficacy and safety analyses. The median treatment duration was 7 months (IQR 4-14), with a median radiologic evaluation time of 10 months (IQR 9-13) and median follow-up of 15 months (IQR 9-22). At data cutoff, 15 (45.5%) patients remained on treatment. Per RECIST 1.1, seven patients (21.2%, [95% CI, 9.0-38.9]) achieved partial response (PR), with a 6-month DCR of 85.2% (23/27). The median PFS was 18.1 months (95% CI, 11.0-28.5). According to Choi criteria, 16 patients (48.5%, [95% CI, 30.8-66.5]) achieved PR, with a 6-month DCR of 77.7% (21/27) and a median PFS of 15.3 months (95% CI, 10.6-NE). Two patients died of tumor progression, and two others with cervical recurrent chordoma died from postoperative complications. NGS analyses revealed copy number deletion (CND) of CDKN2A in 30% (6/20) of cases. Post hoc FISH analysis of 25 specimens identified homozygous deletion (HD) of CDKN2A in 40.0% (10/25), which correlated with poorer outcomes. Adverse events (AEs) occurred in 93.9% (31/33) of patients, with grade 3/4 AEs in 48.5%. Treatment-related AEs led to apatinib dose interruptions in 39.4% and camrelizumab interruptions in 21.2%. Conclusions: The combination of camrelizumab and apatinib demonstrated promising efficacy and manageable toxicity in chordoma treatment. Furthermore, CDKN2A alterations (CND or HD) were associated with poorer outcomes, providing a potential biomarker for therapeutic stratification. Clinical trial information: ChiCTR2100042938 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
molihuakai的应助被文献互助1采纳,获得10
刚刚
bkagyin的应助被rose采纳,获得10
刚刚
maoamo2024发布了新的文献求助10
1秒前
yu完成签到,获得积分10
1秒前
田様的应助被路小雨采纳,获得10
1秒前
1秒前
1秒前
久睡成瘾完成签到,获得积分10
2秒前
清辉影的应助被yuxing采纳,获得10
2秒前
Jan完成签到,获得积分0
2秒前
Tuniverse_发布了新的文献求助10
3秒前
温柔的百川完成签到,获得积分10
3秒前
喂喂喂发布了新的文献求助10
4秒前
Yaoz完成签到,获得积分10
4秒前
许元冬完成签到,获得积分10
4秒前
zft完成签到,获得积分10
4秒前
KBRS完成签到,获得积分10
5秒前
MM完成签到,获得积分10
6秒前
雪雪完成签到,获得积分10
7秒前
Yaoz发布了新的文献求助30
8秒前
明亮绮菱发布了新的文献求助10
8秒前
xiang完成签到,获得积分10
10秒前
10秒前
缥缈幻悲完成签到,获得积分10
10秒前
王明月完成签到,获得积分10
11秒前
彭映梦完成签到 ,获得积分10
12秒前
小小酥被卷了完成签到,获得积分10
13秒前
科研通AI6.4的应助被obito采纳,获得10
15秒前
天真酸奶的应助被obito采纳,获得10
15秒前
CipherSage的应助被明亮绮菱采纳,获得10
15秒前
王明月发布了新的文献求助10
15秒前
Gyqqqq完成签到,获得积分10
16秒前
Owen的应助被feisun采纳,获得10
17秒前
17秒前
难过含烟完成签到 ,获得积分10
18秒前
likun完成签到,获得积分10
18秒前
19秒前
20秒前
科研通AI2S的应助被liquss采纳,获得10
20秒前
王木木要努力完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621